This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Top ETF Stories of 2020 & Picks for 2021
by Neena Mishra
We discuss the 2020 trends and outlook for 2021...
Top ETF of December & Its Best Stocks
by Sweta Killa
We have highlighted the best ETF of December and its best performing stocks.
6 Best Active ETFs of 2020
by Sanghamitra Saha
The year 2020 has been beneficial for equities despite coronavirus outbreak. These active ETFs, however, breezed past the benchmark index.
8 ETFs That Have Gained More Than 100% in 2020
by Sweta Killa
We have presented a bunch of top-performing ETFs from various corners of the market that gained in triple digits from a year-to-date look and will likely continue outperforming, should the trends prevail.
Top Sector ETFs of Record-Setting Last Week
by Sanghamitra Saha
The S&P 500, the Dow Jones and the Nasdaq Composite -- all three indexes touched all-time closing highs to end last week.
5 ETFs Deserving Special Thanks in Pandemic-Stricken 2020
by Sweta Killa
We have highlighted five ETFs from different zones that have been star performers so far this year and deserve special thanks and attention going into the New Year.
ETFs in Focus on Bayer's Bet on Gene Therapy
by Sweta Killa
Bayer has made a big bet on gene therapy by announcing the acquisition of U.S. biotech firm Asklepios BioPharmaceutical for as much as $4 billion.
4 Sector ETFs That Have Doubled This Year
by Sweta Killa
Few sector ETFs have doubled this year amid the coronavirus pandemic.
Why You Should Invest in Genomics ETFs
by Neena Mishra
Genomics ETFs have surged of late; here's why
Biotech ETFs to Shine on Coronavirus Antibodies Progress
by Sweta Jaiswal, FRM
With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.
5 Sector ETFs Gaining in Double Digits to Start October
by Sweta Killa
Wall Street registered back-to-back weekly gains primarily on the back of prospects for another round of fiscal stimulus from Congress.
Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers
by Sweta Jaiswal, FRM
The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.
Biotech ETFs to Gain on Trump's COVID-19 Treatment Protocol
by Sweta Jaiswal, FRM
The progress in Trump's health condition and his treatment protocols are continuously under the purview of market participants and are impacting Wall Street movements.
Healthcare ETFs Pop on Bristol Myers-MyoKardia Deal
by Sweta Killa
These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.
Top-Performing Biotech ETFs Amid the Coronavirus Crisis
by Sweta Jaiswal, FRM
The race to introduce vaccine and treatment of coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.
Top & Flop ETF Zones of First Nine Months of 2020
by Sweta Killa
We have highlighted the best and worst-performing zones and their ETFs in the first nine months of 2020.
Biotech ETFs in Focus as the COVID-19 Vaccine Race Intensifies
by Sweta Jaiswal, FRM
Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.
How Will Biotech ETFs React to Vaccine Makers' Safety Pledge?
by Sweta Jaiswal, FRM
Nine vaccine developers have jointly pledged to observe high ethical standards in conducting clinical studies and manufacturing of vaccines.
Biotech ETFs to Shine Bright on Coronavirus Vaccine Progress
by Sweta Jaiswal, FRM
AstraZeneca's initiation of a phase III study has heated up competition to bring a coronavirus vaccine to the markets.
Top-Performing ETFs of Last Week
by Sanghamitra Saha
Wall Street was moderate last week with the S&P 500 and the Nasdaq gaining about 0.7% and 2.7%, respectively, and the Dow Jones witnessing no movement.
5 Sector ETFs That Have Gained More Than 50% This Year
by Sweta Killa
We highlight five ETFs from different sectors of the broad market that have outperformed and gained at least 50% so far this year.
Late-Stage Coronavirus Vaccine Trials Begin: Biotech ETFs to Gain
by Sweta Jaiswal, FRM
Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.
Biotech ETFs to Gain on Coronavirus Vaccine Progress
by Sweta Jaiswal, FRM
The race to find a coronavirus vaccine is heating up as the latest positive data from progress in trials are being published.
Can Top ETFs of Q2 Continue to Rally in Q3?
by Neena Mishra
We take a look at the best performing ETFs of Q2 that are likely to gain in Q3 as well.
Biotech ETFs to Shine on Pfizer's Coronavirus Vaccine Progress
by Sweta Jaiswal, FRM
Two out of four of Pfizer's coronavirus vaccine candidates, BNT162b1 and BNT162b2, have been granted the 'fast track' designation by the FDA.